Gene · 3003
NIH grants2,103
NIH grants whose papers are about the gene, through NIH's grant-paper links.
961 to 980 of 2,103
Download this page as JSON| Grant | Title | GZMK papers | Newest fiscal year |
|---|---|---|---|
| R01AI130198 | TCR signal strength and iNKT cell subset development | 2 | 2022 |
| R01AI136972 | Genetic regulation and immunological function of ERAP2 haplotypes | 2 | 2022 |
| R01AI137275 | DETERMINING THE ROLE OF THE REPLICATIVE HELICASE IN HUMAN NK CELL DEVELOPMENT | 2 | 2022 |
| R01AR042527 | Oligoclonal T Cell Expansion and Rheumatoid Arthritis | 2 | 2022 |
| R01CA121113 | Large-Scale Genetic Analyses of Human Cancer | 2 | 2022 |
| R01CA234018 | Regulators of Cancer Immunotherapy Response | 2 | 2022 |
| R01HL141852 | Epithelial Protective Effects of Thyroid Hormone Signaling in Fibrosis | 2 | 2022 |
| U01CA232758 | B cell-dependent anti-tumor immunity in ovarian cancer | 2 | 2022 |
| U01CA244452 | Mechanisms of Exosome Driven Immunoregulation of Cancer Progression | 2 | 2022 |
| U01HL145567 | Normal Aging Lung Cell Atlas (NALCA) | 2 | 2022 |
| U54CA232568 | Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers | 2 | 2022 |
| UL1TR002494 | University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI) | 2 | 2022 |
| DP1CA238296 | Forecasting tumor evolution: can the past reveal the future? | 1 | 2022 |
| F30CA250249 | Mechanosensation in tumorigenesis and metastasis | 1 | 2022 |
| F30CA257414 | Multimodal computational models to stratify ovarian cancer patients | 1 | 2022 |
| F30DK121470 | Adaptive immunity in primary sclerosing cholangitis patients at risk for colorectal cancer | 1 | 2022 |
| F30HL143911 | SOX9 Expression Identifies A Novel Alveolar Stem Cell Population | 1 | 2022 |
| F31CA246901 | Single Cell Dissection of Epigenetic and Tumor Ecosystem Dynamics During Pancreatic Cancer Progression | 1 | 2022 |
| F31CA250320 | The importance of CD4+ tumor-infiltrating lymphocytes (TIL) in adoptive cell transfer | 1 | 2022 |
| F31CA261056 | Elucidating Synergy of Enzalutamide and Src Kinase Inhibitors in Castration-Resistant Prostate Cancer | 1 | 2022 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3003/grants?page=49